Citius Pharmaceuticals Valuation

Q: What is the Fair Price of CTXR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CTXR ($0.13) is trading below our estimate of [[fair value]] ($7.88)

Is CTXR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CTXR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CTXR ($0.13) is trading below our estimate of fair value ($7.88)

Significantly Below Fair Value: CTXR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CTXR?

Key metric: As CTXR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CTXR. This is calculated by dividing CTXR's market cap by their current book value.
What is CTXR's PB Ratio?
PB Ratio	0.3x
Book	US$85.68m
Market Cap	US$25.85m

CTXR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-0.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CTXR's PB Ratio compare to its peers?

The above table shows the PB ratio for CTXR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.9x
IRD Opus Genetics	0.9x	64.9%	US$31.9m
GRCE Grace Therapeutics	0.6x	49.6%	US$33.3m
IBO Impact BioMedical	1x	n/a	US$30.0m
IXHL Incannex Healthcare	5.3x	n/a	US$34.9m
CTXR Citius Pharmaceuticals	0.3x	53.0%	US$25.8m

Price-To-Book vs Peers: CTXR is good value based on its Price-To-Book Ratio (0.3x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does CTXR's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

22 Companies	Price / Book	Estimated Growth	Market Cap
SHWZ Medicine Man Technologies	0.1x	n/a	US$8.82m
TNFA TNF Pharmaceuticals	0.2x	n/a	US$3.69m
UPC Universe Pharmaceuticals	0.1x	n/a	US$3.04m
CYTO Altamira Therapeutics	0.2x	-5.9%	US$1.44m

22 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: CTXR is good value based on its Price-To-Book Ratio (0.3x) compared to the US Pharmaceuticals industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is CTXR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CTXR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CTXR's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

4.7%

-4.8%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

1.3%

15.1%